Skip to content
10-Q

Quarterly Report

AGIOS PHARMACEUTICALS, INC. AGIO

0001439222-26-000073

← back to feed
Filed
Apr 29, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 24, 2026 59.47M sh
Shares Diluted Q1 2026 · Mar 31, 2026 58.78M sh
Shares Diluted Q1 2026 · Mar 31, 2025 57.46M sh
Capex Q1 2026 · Mar 31, 2026 $769K
Capex Q1 2026 · Mar 31, 2025 $766K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$118.92M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$111.49M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $113.6M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $89.13M
Stockholders Equity Q1 2026 · Mar 31, 2026 $1.11B
Stockholders Equity Q1 2026 · Dec 31, 2025 $1.19B
Stockholders Equity Q1 2026 · Mar 31, 2025 $1.47B
Stockholders Equity Q1 2026 · Dec 31, 2024 $1.54B
Current Liabilities Q1 2026 · Mar 31, 2026 $58.85M
Current Liabilities Q1 2026 · Dec 31, 2025 $82.21M
Total Liabilities Q1 2026 · Mar 31, 2026 $75.88M
Total Liabilities Q1 2026 · Dec 31, 2025 $104.11M
Current Assets Q1 2026 · Mar 31, 2026 $834.84M
Current Assets Q1 2026 · Dec 31, 2025 $942.05M
Total Assets Q1 2026 · Mar 31, 2026 $1.18B
Total Assets Q1 2026 · Dec 31, 2025 $1.3B
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.69
Eps Diluted Q1 2026 · Mar 31, 2025 −$1.55
Eps Basic Q1 2026 · Mar 31, 2026 −$1.69
Eps Basic Q1 2026 · Mar 31, 2025 −$1.55
Sga Expense Q1 2026 · Mar 31, 2026 $48.3M
Sga Expense Q1 2026 · Mar 31, 2025 $41.53M
Rd Expense Q1 2026 · Mar 31, 2026 $81.15M
Rd Expense Q1 2026 · Mar 31, 2025 $72.74M
Net Income Q1 2026 · Mar 31, 2026 −$99.11M
Net Income Q1 2026 · Mar 31, 2025 −$89.29M
Operating Income Q1 2026 · Mar 31, 2026 −$110.03M
Operating Income Q1 2026 · Mar 31, 2025 −$106.63M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $1.32M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $1.09M
Revenue Q1 2026 · Mar 31, 2026 $20.75M
Revenue Q1 2026 · Mar 31, 2025 $8.73M